Could this AI technique be the solution to the Silent Epidemic?
Some challenges in the health sector remain hidden from the spotlight. however, when the challenge is the nation’s fourth leading cause of death, accounts for up to 35% of hospital admissions, and costs $528 billion annually, finding a solution is urgent. priority.
Adverse drug reactions (ADRs) are now an epidemic.
Polypharmacy, usually defined as the regular use of at least five medications, is common among older adults and younger at-risk groups. It increases the risk of adverse drug reactions, drug-related hospitalizations, and death. Adverse drug reactions include a variety of unintended and harmful consequences that result from the use of drugs. These reactions can be caused by a variety of factors, including individual genetics, drug interactions, and underlying health conditions.
As the number of drugs taken increases, the risk of adverse drug reactions (ADRs) increases. A patient taking 5 or more medications has a 58% chance of experiencing an adverse drug event; when a patient takes more than 8 medications, that number can reach 82%.
Adverse Drug Reaction Scale
Dr. “We’re using artificial intelligence to personalize and augment high-quality drug therapy. Our breakthrough technology enables healthcare organizations (such as payers and health systems) to improve the quality and scale of access to drug therapy, quantify clinical and financial impact, and reduce the overall cost of care.”
“Previous attempts to solve this problem lacked significant personalization and scalability due to technical and human limitations,” he says. “Comprehensive medication reviews, usually performed by pharmacists, assess the effectiveness of a patient’s medication as well as the risks associated with the medication. Comprehensive drug reviews can reduce ADR risks and adverse drug-related outcomes, but this complex, manual, and time-consuming process limits its widespread use and availability. Computer-based solutions include clinical decision support software that addresses a narrow view of the problem. Common clinical decision support software includes drug-drug interaction systems that do not distinguish between influencing factors such as patients’ health status, medical history, and demographics, leading to risks of medication omission and many false positive signals that are largely ignored by clinicians. : .
“To pinpoint drug risks and provide safer and more effective drug treatments, we need to look at patients holistically,” he explains. “Our demographics, medications, medical history, lifestyle, and even lab results affect our risk for ADRs. There is no single dose of medication, and two patients taking the exact same medication may be exposed to different drug risks and experience different outcomes.”
B. He realized that there was little access to comprehensive medication management programs that optimized medication use. After countless hours of manual drug analysis, he was unable to find a solution that actually reduced analysis time while maintaining high clinical standards.
Realizing that millions of patients suffer from medication-related complications related to polypharmacy, he is on a mission to augment his work with technology. Recognizing the impact of AI-based technologies on personalizing and automating comprehensive drug reviews, he collaborated with technology and AI experts Avishai Ben-Tovim and Yuval Kalev to develop technology that democratizes access to optimized drug treatment and prevents drug-related problems. morbidity and mortality.
“We were able to create the first multi-layered, dedicated and consistent risk analysis system for polypharmacy patients that could handle these complex cases and generate accurate clinical recommendations for treatment optimization and risk reduction,” he says. “Our medication management platform automatically performs comprehensive drug risk analysis for the entire population, helping clinical teams reach the entire population at risk. Our algorithms analyze thousands of pharmacologic and medical parameters for each patient, including member demographics, medications and medical history, medical conditions, and lab results, enabling us to identify accurate and immediate health risks. They then generate evidence-based clinical recommendations for risk reduction.”
Some healthcare organizations are now starting to adopt MDI’s medication management platform, but “it’s not yet widely used.” Established organizations such as healthcare payers tend to approach new technologies with caution and hesitation. We have devoted the last two years to validating the results. through collaboration with prominent healthcare organizations. In addition, we have developed the ability to provide clinical and financial projections for our solution even before signing a formal agreement, without prior commitment.” B.
Despite increased efforts to prevent ASDs in the past decade, measuring exposure without appropriate technology can be difficult. “We’re seeing an increase in drug-related hospitalizations and death rates, and we know that most of these cases are preventable. Medicines can heal us or make us sicker, and it depends on how we use them. “The main thing is to weigh the benefits and risks of the patient’s medicines. unfortunately, this is not always an easy or simple task. Studies show that every drug we add to a patient’s drug list increases the risk of an adverse drug event by 7-10%, so we need to be vigilant. A comprehensive review of patients’ medications is critical to identify drug-related risks before they become a dangerous problem. We recommend that patients with chronic conditions undergo a comprehensive medication review at least once a year.”
“Less is sometimes more, especially when treating patients with polypharmacy,” she adds. “Prescribing, which is more common these days, means reducing medications to the lowest effective dose or stopping them when a patient’s health changes so that the burden or potential harm of the medication outweighs the benefits of taking the medication. We encourage wider use of this important process.”
“We encourage people to closely follow the transformation that is taking place in this industry and address this pressing issue that affects millions of people every year. This silent epidemic can be significantly mitigated by the use of innovative technologies. We hope that all patients will soon have access to the safest and most effective personalized medicine treatment,” he concludes.
#solution #4th #leading #death
Image Source : www.forbes.com